Background: Pseudoprogression (PsP) is characterized by therapy-associated but
Statement of Translational Relevance
Tumor progression in patients with glioblastoma inevitably occurs despite treatment according to state of the science. A significantly increasing contrast-enhancement on MRI appearing later than 12 weeks following completion of last radiotherapy is usually considered a sign of tumor progression. Nevertheless, increasing contrastenhancement on MRI may also reflect late pseudoprogression. Late pseudoprogression is diagnosed when the initially increasing contrast-enhancement does not increase in size further on a follow-up MRI performed about 4-8 weeks later. For many patients with concomitant clinical deterioration, however, waiting for a follow-up MRI may be not applicable. With the presented data we show that O-(2- 
Methods:
Twenty-six patients with glioblastoma that presented with increasing contrast-enhancing lesions later than 3 months after completion of RCX underwent 18 F-FET-PET. Maximum and mean tumor/brain ratios (TBR max , TBR mean ) of 18 F-FET uptake as well as time-to peak (TTP) and patterns of the time-activity curves were determined. The final diagnosis of true progression vs. latePsP was based on followup MRI using RANO criteria.
Results: LatePsP occurred in seven patients with a median time from RCX completion of 24 weeks while the remaining patients showed true tumor progression.
TBR max and TBR mean were significantly higher in patients with true progression than in patients with latePsP (TBR max 2.4±0.1 vs. 1.5±0.2, p=0.003; TBR mean 2.1±0.1 vs.
1.5±0.2, p=0.012) while TTP was significantly shorter (mean TTP 25±2 vs. 40±2 min, p<0.001). ROC analysis yielded an optimal cut-off of 1.9 for TBR max to differentiate between true progression and latePsP (sensitivity 84%, specificity 86%, accuracy 85%, p=0.015).
Conclusion: O-(2-[

Introduction
Despite surgery, radiation therapy and chemotherapy, the overall survival of patients with glioblastoma (GBM) is short with a median of about 17 months (1). Considering the very restricted therapeutic options for salvage therapy, it is important that temozolomide (TMZ) chemotherapy is provided for an adequately long time and not terminated prematurely based on misinterpretation of post-radiation treatment effects. Among the latter, pseudoprogression may mimic true recurrent tumor.
Pseudoprogression is a retrospective diagnosis built on increasing contrast enhancement on MRI consistent with true tumor progression that eventually remains stable or is even regressive during further follow-up without changing the treatment (2-7). Pseudoprogression after previous radiochemotherapy with temozolomide is more frequently observed in patients with a methylated MGMT promoter gene (8) .
Treatment-related changes such as pseudoprogression are thought to be secondary to radiosensitizing effects of temozolomide, thus predominantly ocurring in patients with methylated MGMT promoter (7) . Pseudoprogression may be a sign for tumor necrosis rather than for tumor progression and therefore may reflect therapeutic efficacy.
There are no absolutely strict criteria as to when pseudoprogression is supposed to occur relative to radiotherapy. As defined by the Response Assessment in NeuroOncology (RANO) working group, pseudoprogression occurs within 12 weeks after completion of radiation therapy (7) . In a recent report, however, we pointed out that pseudoprogression may well occur beyond 12 weeks and was designated late pseudoprogression (5) . Early and late pseudoprogression may lie at the opposite sites of a temporal continuum. It is possible that pseudoprogression may be more
Research. influenced by chemotherapy than early psuedoprogression. Also, late pseudoprogression may be particularly frequent under the influence of temozolomide/lomustine combination therapy (5) .
If an increasing contrast-enhancing lesion on MRI indicates (late) pseudoprogression, the current gold standard is to perform follow-up MRIs to evaluate changes in lesion size. Consequently, a diagnosis of (late) pseudoprogression can only be made retrospectively based on follow-up MRI. It would be, however, advantageous for patient management if pseudoprogression could be identified at the earliest possible time point when the increasing contrastenhancing lesions are detected for the first time. This is particularly important for patients with greatly increasing contrast-enhancing lesions and deteriorating clinical status. These patients might not be able to wait 4-8 weeks for a follow-up MRI to have decided whether secondary surgery or any other therapeutic adjustments are needed.
Position-Emission-Tomography (PET) using radiolabeled amino acids such as O-(2- (10) . Also, 18 F-FET PET has been shown to be useful in treatment planning (11) , detecting malignant progression in low grade glioma (12) , identifying glioma in newly diagnosed cerebral lesions (13) and the diagnosis of recurrent malignant glioma (13, 14) . A disrupted blood-brain barrier (BBB), as indicated by contrast
Research. 
Materials and Methods
Study design
For this retrospective analysis, our data bank was searched for histologically confirmed glioblastoma patients meeting the following characteristics: (1) patients experiencing increasing contrast-enhancing lesions on MRI (+25% in 2 perpendicular diameters and/or any new lesion according to RANO (17) , lesion size >10 mm) more than 12 weeks after the end of radiotherapy, or, in case of treatment with alkylating chemotherapy only, beginning of chemotherapy; (2) patients having a 
PET Imaging with 18 F-FET
The amino acid 18 F-FET was produced as described previously (18, 19) . According to the German guidelines for brain tumor imaging using labelled amino acid analogues, all patients remained fasted for at least 12 h before PET scanning (20) . (20) . Mean amino acid uptake in the tumor was determined by a 2-dimensional autocontouring process using a tumor-to-brain ratio (TBR) of 1.6 as described previously (13), for maximal amino acid uptake a circular ROI with a diameter of 1.6 cm was centered on maximal tumor uptake. Maximum and mean tumor-brain-ratios (TBR max , TBR mean ) were calculated by dividing the mean SUV of these tumor ROIs by the mean SUV of normal brain in the PET scan. 
PET Data Analysis
a volume of 2 ml centered on maximal tumor uptake and of a reference ROI in the unaffected brain tissue (as described above) to the entire dynamic data set. Time-topeak (TTP; time in minutes from the beginning of the dynamic acquisition up to the maximum SUV of the lesion) was determined. Furthermore, as previously descibed (12, 21) , the TACs of each lesion were assigned to one of the following curve patterns: constantly increasing 18 F-FET-uptake without identifiable peak uptake (pattern I); 18 F-FET-uptake peaking at a midway point (> 20-40 min) followed by a plateau or a small descent (pattern II); and 18 F-FET-uptake peaking early (≤ 20 min)
followed by a constant descent (pattern III). The assignment of TACs to the various curve patterns was performed by 3 experienced raters (NG; KJL; GS).
Diagnosis of True Progression
The diagnosis of tumor progression was made when progressive contrast-enhancing lesions according to RANO criteria (17) were noted in initial MRI and when further progression of contrast-enhancement was noted in a follow-up MRI at least 4 weeks later. By contrast, the diagnosis of pseudoprogression was applied when the followup MRI showed stabilization or regression of the contrast-enhancing lesions.
Statistics
Descriptive statistics are reported as mean and standard error of mean (SEM). For the purpose of comparing two means, a two-sided Student t test for independent samples was used. A p value of less than 0.05 was regarded as significant. The diagnostic performance of TBR values to distinguish latePsP from true progression was assessed by receiver-operating-characteristic (ROC) curve analyses using the results of follow-up MRI as reference. The optimal cut-off was the value where the square of the difference between sensitivity and specificity was minimized; i.e., where both sensitivity and specificity were highest. Moreover, the area under the ROC curve (AUC), its standard error (SE) and its level of significance were determined as an estimation of diagnostic quality. The diagnostic performance of curve patterns alone to assess for latePsP was determined by a Fisher exact test for 2 x 2 contingency tables. Statistical analysis was done using Stata (release 13. 
Results
Patient characteristics
The study population comprised of 26 adult patients (Table 1) Four patients were analyzed while being in second-line therapy (after TMZ-based radiochemotherapy as primary therapy) with alkylating chemotherapy (one patient with CCNU/TMZ, one patient with procarbazine and CCNU, one patient with CCNU anly, and one patient with TMZ); two of them additionally had re-irradiation (Table 1) .
Diagnosis of tumor progression versus latePsP
In all patients MRI scan analysis was carried out by two independent investigators (Table 1) . MGMT promoter methylation status was tested methylated in 6 out of 7 patients with latePsP (86%). In one patient, the MGMT promoter was not methylated. In patients with true progression, the MGMT promoter gene was found methylated in 11/19 patients (58%). 
ROC analysis
ROC analysis yielded an optimal cut-off of 1.9 for TBR max to differentiate between true progression and latePsP (sensitivity 84 %, specificity 86 %, accuracy 85 %, AUC 0.88±0.07; 95%CI 0.73 -1.0, p=0.015) (Figure 3) . The same cut-off (1.9) was obtained for TBR mean which achieved a slightly poorer yet significant diagnostic performance (sensitivity 74 %, specificity 86 %, accuracy 77 %, AUC 0.86±0.07; 
Discussion
The results of this study suggest that Patients with O6-methylguanine methyltransferase (MGMT)-methylated glioma are more likely to develop pseudoprogression, amounting to an incidence of up to 31% as compared with 5% in patients with non-methylated tumors (8, 17, 22) . Accordingly, our study found that almost all patients with latePsP had a methylated MGMT promoter. Nevertheless, one patient with a non-methylated MGMT promotor was diagnosed with latePsP. Therefore, patients with non-methylated MGMT promotor also should be considered for latePsP.
TBR max and TBR mean were both useful in predicting progression with TBR max providing a slightly higher diagnostic accuracy in this series of patients. In our cohort of patients with glioblastoma, diagnostic accuracy for identifying true progression was highest at a threshold of 1.9 for TBR mean and TBR max . This cut-off value is close to the previously reported cut-off for TBR max (2.3) for distinguishing glioblastoma patients with early pseudoprogression from true early progressive disease (9) .
Similarly, the presence of curve patterns type II and III were predictive for true progression. TTP of 18 F-FET uptake has already been described as a helpful parameter for determining malignant progression in patients with low-grade glioma (9) and as a prognostic marker in high-grade glioma (23). In our series of patients TTP confirmed these finding by showing significant differences between true tumor progression and latePsP.
Our study supports further larger scale prospective studies that include histopathologic confirmation to confirm the high diagnostic accuracy of This study has several limitations with the predominant one being its small sample size. The small sample size accounts for fragile statistical results. Additionally, the retrospective nature of this study inadvertently leads to selection bias, limiting the power of our conclusions. Therefore, the results here should be interpreted with caution. However, our study documents for the first time that 18 F-FET-PET may be a valuable tool in determining latePsP, a condition, whose underdiagnosis might have a serious negative impact on survival for the affected patient because an effective treatment could be erroneously terminated. Thus, this method should be further evaluated in rigorously controlled and prospective trials.
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